CEBPA and neoplasm: Mina Therapeutics developed MTL-CEBPA, a nanoformulated small double-stranded 2′-O-methylated RNA that can specifically activate the expression of the tumor suppressor CEBPA, preventing activation of Wnt/β-catenin signaling [308,309].